Volume 13, Number 3—March 2007
Research
Population-based Laboratory Surveillance for AmpC β-Lactamase–producing Escherichia coli, Calgary
Johann D.D. Pitout*
, Daniel B. Gregson*, Deirdre L. Church*, and Kevin B. Laupland*
, Daniel B. Gregson*, Deirdre L. Church*, and Kevin B. Laupland*
Table
Features of Escherichia coli β-lactamases isolated from Calgary Health Region, 2000–2003
| Feature* | CMY types (n = 125), no. (%) | Non-CMY types (n = 244), no. (%) | p value |
|---|---|---|---|
| Female | 105 (84) | 205 (84) | 1.0 |
| Community-onset | 104 (83) | 204 (84) | 1.0 |
| Resistant to | |||
| Ciprofloxacin | 10 (8) | 23 (9) | 0.6 |
| Gentamicin | 28 (22) | 26 (11) | 0.004 |
| Tobramycin | 13 (10) | 19 (8) | 0.4 |
| Trimethoprim-sulfamethoxazole | 29 (23) | 44 (18) | 0.3 |
*Median age for those with CMY types was 54.3 (interquartile range 27.7–76.1); median age for those with non-CMY types was 50.5 (interquartile range 26.6–73.3).
Page created: June 29, 2010
Page updated: June 29, 2010
Page reviewed: June 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.